<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1529782F-9068-4364-888E-46E4FC4881F5"><gtr:id>1529782F-9068-4364-888E-46E4FC4881F5</gtr:id><gtr:name>Nottingham Trent University</gtr:name><gtr:address><gtr:line1>Burton Street</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG1 4BU</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>Sch of Molecular Medical Sciences</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1529782F-9068-4364-888E-46E4FC4881F5"><gtr:id>1529782F-9068-4364-888E-46E4FC4881F5</gtr:id><gtr:name>Nottingham Trent University</gtr:name><gtr:address><gtr:line1>Burton Street</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG1 4BU</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D755C1A9-6CD1-47E1-B163-66A5B98CD8A2"><gtr:id>D755C1A9-6CD1-47E1-B163-66A5B98CD8A2</gtr:id><gtr:firstName>Christina</gtr:firstName><gtr:surname>Perry</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ008001%2F1"><gtr:id>412D9F9B-3604-4427-B501-25A1394D012D</gtr:id><gtr:title>Human apurinic/apyrimidinic endonuclease (APE1) is a novel drug target in glioma.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/J008001/1</gtr:grantReference><gtr:abstractText>Advanced glioma is a devastating disease. Chemotherapeutic agents and radiation exert anticancer effects by damaging tumour cell DNA. However, DNA damage is rigorously monitored and repaired by the DNA repair machinery and this contributes to therapy resistance and poor outcomes in patients. DNA repair inhibition is a promising strategy to improve efficacy in glioma patients undergoing cytotoxic therapy. The ability of PARP inhibitors to not only potentiate chemotherapy and radiotherapy but also to induce synthetic lethality in BRCA deficient cancers confirm that BER modulation is also a new area for personalized cancer medicine and that additional factors within BER are also potential synthetic lethality targets. Human apurininc/aprimidinic endonuclease (APE1) is a critical protein in BER. The host laboratory has isolated novel small molecule inhibitors of APE1. The current research proposal aims to evaluate APE1 in glioma. The project will evaluate the ability of APE1 inhibitors to potentiate cyotoxicity of chemotherapy and radiotherapy in glioma. Studies using APE1 inhibitors will be complemented by studies where APE1 gene will be knocked-out of glioma cells. The expression of proteins involved in DNA repair (including APE1) will be investigated in samples from 200 patients with glioma to assess whether associations exist between expression of these proteins and findings on brain imaging. Ethical approval for this arm of the study has already been obtained.

In conclusion, the evaluation of APE1 inhibitors in glioma will result in a new treatment strategy for this devastating disease.</gtr:abstractText><gtr:technicalSummary>Aims: APE1 is important in DNA base excision repair and redox regulation. APE1 is linked to glioma pathogenesis, radio- and chemo-resistance. This proposal aims to investigate the potential of APE1 inhibition in glioma.
Objectives: 1) To show that APE1 inhibitors potentiate the cytotoxicity of MMS, temozolomide (TMZ) and ionising radiation under normoxic and hypoxic conditions, including in APE1 knockout cells. 2) To investigate synthetic lethality strategy using APE1 inhibitors in ATM, ATR, PTEN and RAD51 deficient cells and compare to wild type cells. 3) To correlate APE1, ATM, RAD51 and ATR expression in human glioma to clinicopathological and neuroradiological features.
Methodology: Tissue culture investigations (MTS and clonogenic assays): APE1 inhibitors will be tested in glioma cell lines [U89MG/SNB19/U373V/TMZ resistant (SNB19VR and U373VR)] for their inherent toxicity. At relatively non-toxic concentrations the ability of APE1 inhibitors to potentiate the cytotoxicity of MMS, TMZ and ionising radiation (0 to 10 Gy) will be investigated. The ability of APE1 inhibitors to selectively target hypoxic cells under hypoxic conditions will be conducted. Similar studies will be conducted in APE1 knockout cells. APE1 and PARP inhibitor (positive control) will be tested for synthetic lethality targeting in ATM, ATR, PTEN and RAD51 deficient cells and compared to wild type cells. Functional studies in cells include: Aldehyde reactive probe, neutral COMET assay, gamma-H2AX immunocytochemistry, FACS analyses, and cell proliferation, migration and invasion assays. Clinicopathological and neuroradiological correlations of APE1 and RAD51 expression in glioma tumours will be studied by immunohistochemistry. 

Scientific and medical opportunities of the study: This proposal will enhance our knowledge of APE1 biology in cancer and lead to a novel treatment strategy for glioma. Radiobiological analysis to be conducted in this study is a key priority area for the MRC</gtr:technicalSummary><gtr:potentialImpactText>This work is essentially preclinical evaluation of a promising new approach to treat glioma. The current efforts in the host laboratory are focused on hit to lead conversion and optimisation for pharmaceutical application. A comprehensive freedom to operate search has been undertaken by the university's technology transfer office. A broad chemical-class patent application for APE1 inhibitors has been filed. 

Pharmacological inhibition of DNA repair is a promising new strategy to improve anti-cancer activity of cytotoxic agents and improve therapeutic efficacy. This proposal, which builds on a significant body of previous work on APE-1 inhibition in the host laboratory, outlines a programme of work which will result in new treatments for patients with glioma within 5-10 years.

Radiobiological analysis to be conducted in this study is a key priority area for the MRC.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>226433</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Translational Neuroimaging</gtr:department><gtr:description>Immunohistochemistry on glioma sections</gtr:description><gtr:id>F7BFE33A-DA2D-4EF3-9877-1B634E3A03DA</gtr:id><gtr:impact>A paper has been published incorporating data on the association between APE1, PTEN, PMS2, and NBN protein expression and survival in glioma.</gtr:impact><gtr:outcomeId>JxJgkk58BMj-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators have been involved in obtaining consent for patients and collecting clinicopathological and radiological data.</gtr:partnerContribution><gtr:piContribution>We have performed immunohistochemical analysis of 88 human glioma slides for APE1, PTEN, PMS2, NBN and ATM expression. Further analysis will be performed for additional DNA repair markers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nottingham Trent University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Arts and Science</gtr:department><gtr:description>Bioinformatics - DNA repair gene prognostic index</gtr:description><gtr:id>4BBB8A19-12B6-4719-BBA6-E052F4EB506D</gtr:id><gtr:impact>A paper has been published incorporating a prognostic score based on expression data for DNA repair genes in patients with glioma.</gtr:impact><gtr:outcomeId>MSpJNo9kYCS-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators have provided statistical input for univariate, multivariate and artificial neural network analysis.</gtr:partnerContribution><gtr:piContribution>We have identified publically available gene expression databases with data on over 100 DNA repair genes. We have investigated the prognostic value of these genes in patients with glioblastoma.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>250</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NCRI Prize Award 2014</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>National Cancer Research Institute (NCRI)</gtr:fundingOrg><gtr:id>92B9634D-50B2-4706-A3B2-5FE66A3EF799</gtr:id><gtr:outcomeId>5451117a8ec831.35720996</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>EA41EC35-6E4E-4A57-B224-D17714D5E4F9</gtr:id><gtr:title>Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?</gtr:title><gtr:parentPublicationTitle>Antioxidants &amp; redox signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dceda89d0980f5e0c093daf60a15668"><gtr:id>1dceda89d0980f5e0c093daf60a15668</gtr:id><gtr:otherNames>Abdel-Fatah TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1523-0864</gtr:issn><gtr:outcomeId>54510a4d728440.30393375</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97030D4B-B739-48AF-8875-A27D74EEF495</gtr:id><gtr:title>Dissecting DNA repair in adult high grade gliomas for patient stratification in the post-genomic era.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dae38c24849ba6bb19508ffd1bbfeee2"><gtr:id>dae38c24849ba6bb19508ffd1bbfeee2</gtr:id><gtr:otherNames>Perry C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>54510ac99383c9.40131007</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FCB0A14-B426-49A1-BD6E-6E142F09FF0C</gtr:id><gtr:title>Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers.</gtr:title><gtr:parentPublicationTitle>Breast cancer research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3f930c0ca29c6f0ee9a1b0017e4d824"><gtr:id>d3f930c0ca29c6f0ee9a1b0017e4d824</gtr:id><gtr:otherNames>Abdel-Fatah T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-6806</gtr:issn><gtr:outcomeId>54510af455df62.47856775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BBE15CF-96F7-4829-A10F-F57B96E46D5F</gtr:id><gtr:title>DNA polymerase ? deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts.</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dceda89d0980f5e0c093daf60a15668"><gtr:id>1dceda89d0980f5e0c093daf60a15668</gtr:id><gtr:otherNames>Abdel-Fatah TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn><gtr:outcomeId>54510b4f4df683.19547995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>319B213D-5952-4ACD-A1BA-9BCA9EE36F56</gtr:id><gtr:title>DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dceda89d0980f5e0c093daf60a15668"><gtr:id>1dceda89d0980f5e0c093daf60a15668</gtr:id><gtr:otherNames>Abdel-Fatah TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>585d6e3cec1919.44015426</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B9F1576-E92C-45CB-9856-DF32BDFE2A60</gtr:id><gtr:title>Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer.</gtr:title><gtr:parentPublicationTitle>Breast cancer research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dceda89d0980f5e0c093daf60a15668"><gtr:id>1dceda89d0980f5e0c093daf60a15668</gtr:id><gtr:otherNames>Abdel-Fatah TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-6806</gtr:issn><gtr:outcomeId>54510b7491a013.18337504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7374EB9D-288E-4C96-AAE3-0003334CC667</gtr:id><gtr:title>Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/517aebfddb20c2c2c29b535b3547f2bd"><gtr:id>517aebfddb20c2c2c29b535b3547f2bd</gtr:id><gtr:otherNames>Sultana R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_22962_ne_0057098</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0CEDA0E-5537-4BAB-BEBA-35C37CCCCCD5</gtr:id><gtr:title>Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3e24930f6718b1a4987f8397e40d5e5"><gtr:id>f3e24930f6718b1a4987f8397e40d5e5</gtr:id><gtr:otherNames>Albarakati N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn><gtr:outcomeId>54510a9792fd87.41263818</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J008001/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>